Certified Diabetes Educator Practice Exam

SGLT2 inhibitors are known to potentially lead to ketoacidosis in diabetic patients. This class of medications works by preventing the reabsorption of glucose in the kidneys, promoting its excretion in urine. While SGLT2 inhibitors are effective in lowering blood glucose levels and can benefit weight management and cardiovascular health, they also have a rare but significant risk of leading to diabetic ketoacidosis (DKA), particularly in patients with type 1 diabetes or under specific conditions such as dehydration, illness, or a very low carbohydrate intake.

The mechanism behind this risk involves a combination of factors; when insulin levels are low, such as in cases of insufficient insulin therapy or during acute illness, the body may compensate by increasing ketone production. SGLT2 inhibitors can exacerbate this condition since they promote glucosuria and therefore could contribute to an environment where DKA is more likely to develop, especially in predisposed individuals. This underscores the importance of monitoring and educating patients about the risks associated with these medications.